Extensive testing or focused testing of patients with elevated liver enzymes

Journal of Hepatology

Volumn 66, Issue 2, 2017, Pages 313-319

  Tapper, Elliot B ^a   Saini, Sameer D ^a   Sengupta, Neil ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Alcohol; Cost effectiveness; Hepatitis C; Liver disease; Liver function tests; NAFLD; Serum aminotransferases

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ARTICLE; CLINICAL EVALUATION; DIAGNOSTIC TEST; DISEASE SIMULATION; ECONOMIC ASPECT; FALSE POSITIVE RESULT; GREAT BRITAIN; HEALTH CARE COST; HUMAN; HYPERTRANSAMINASEMIA; LIVER BIOPSY; LIVER DISEASE; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; UNITED STATES; ADULT; BLOOD; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; ENZYMOLOGY; FEMALE; LIVER; LIVER FUNCTION TEST; MALE; PATHOLOGY; PATIENT CARE; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DECISION MAKING, COMPUTER-ASSISTED; FEMALE; HUMANS; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; PATIENT CARE MANAGEMENT;

EID: 85005978145     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.09.017     Document Type: Article

References (43)

1. [1] Clark, J.M., Brancati, F.L., Diehl, A.M., The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98 (2003), 960–967.
2. [2] Armstrong, M.J., Houlihan, D.D., Bentham, L., Shaw, J.C., Cramb, R., Olliff, S., et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol 56 (2012), 234–240.
3. [3] Lazo, M., Hernaez, R., Eberhardt, M.S., Bonekamp, S., Kamel, I., Guallar, E., et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988–1994. Am J Epidemiol 178 (2013), 38–45.
4. [4] Daniel, S., Ben-Menachem, T., Vasudevan, G., Ma, C.K., Blumenkehl, M., Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 94 (1999), 3010–3014.
5. [5] Sorbi, D., McGill, D.B., Thistle, J.L., Therneau, T.M., Henry, J., Lindor, K.D., An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities. Am J Gastroenterol 95 (2000), 3206–3210.
6. [6] Pendino, G.M., Mariano, A., Surace, P., Caserta, C.A., Fiorillo, M.T., Amante, A., et al. Prevalence and etiology of altered liver tests: a population-based survey in a mediterranean town. Hepatology 41 (2005), 1151–1159.
7. [7] Boonstra, K., Beuers, U., Ponsioen, C.Y., Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 56 (2012), 1181–1188.
8. [8] Muri, Boberg K., Prevalence and epidemiology of autoimmune hepatitis. Clin Liver Dis 6 (2002), 635–647.
9. [9] Bacon, B.R., Adams, P.C., Kowdley, K.V., Powell, L.W., Tavill, A.S., Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54 (2011), 328–343.
10. [10] Tapper, E.B., Rahni, D.O., Arnaout, R., Lai, M., The overuse of serum ceruloplasmin measurement. Am J Med, 126, 2013, 926, e921–e926. e925.
11. [11] Silverman, E.K., Miletich, J.P., Pierce, J.A., Sherman, L.A., Endicott, S.K., Broze, G.J. Jr, et al. Alpha-1-antitrypsin deficiency. Am Rev Respir Dis 140 (1989), 961–966.
12. [12] Van Ness, M.M., Diehl, A.M., Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes?. Ann Intern Med 111 (1989), 473–478.
13. [13] Pratt, D.S., Kaplan, M.M., Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 342 (2000), 1266–1271.
14. [14] Green, R.M., Flamm, S., AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 123 (2002), 1367–1384.
15. [15] Lichtenstein, M.J., Pincus, T., How useful are combinations of blood tests in “rheumatic panels” in diagnosis of rheumatic diseases?. J Gen Intern Med 3 (1988), 435–442.
16. [16] Tapper, E.B., Patwardhan, V.R., Curry, M., Low yield and utilization of confirmatory testing in a cohort of patients with liver disease assessed for alpha-1 antitrypsin deficiency. Dig Dis Sci, 2014, 1–6.
17. [17] Morgan, D.J., Wright, S.M., Dhruva, S., Update on medical overuse. JAMA Intern Med 175 (2015), 120–124.
18. [18] Tapper, E.B., Sengupta, N., Lai, M., Horowitz, G., Understanding and reducing ceruloplasmin overuse with a decision support intervention for liver disease evaluation. Am J Med, 2015.
19. [19] Smith, M., Saunders, R., Stuckhardt, L., McGinnis, J.M., Best care at lower cost: the path to continuously learning health care in America. 2013, National Academies Press.
20. [20] Berwick, D.M., Hackbarth, A.D., Eliminating waste in US health care. JAMA 307 (2012), 1513–1516.
21. [21] Welch, H.G., Passow, H.J., Quantifying the benefits and harms of screening mammography. JAMA Intern Med 174 (2014), 448–454.
22. [22] Hunink, M.G.M., Weinstein, M.C., Wittenberg, E., Drummond, M.F., Pliskin, J.S., Wong, J.B., et al. Decision making in health and medicine: Integrating evidence and values. 2014, Cambridge University Press, Cambridge, UK.
23. [23] Petrou, S., Gray, A., Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting. BMJ, 342, 2011.
24. [24] Siegel, J.E., Weinstein, M.C., Russell, L.B., Gold, M.R., Recommendations for reporting cost-effectiveness analyses. JAMA 276 (1996), 1339–1341.
25. [25] Ioannou, G.N., Boyko, E.J., Lee, S.P., The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999–2002. Am J Gastroenterol 101 (2006), 76–82.
26. [26] Björnsson, E.S., Bergmann, O.M., Björnsson, H.K., Kvaran, R.B., Olafsson, S., Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 144 (2013), 1419–1425, e1413.
27. [27] Cauza, E., Maier-Dobersberger, T., Polli, C., Kaserer, K., Kramer, L., Ferenci, P., Screening for Wilson's disease in patients with liver diseases by serum ceruloplasmin. J Hepatol 27 (1997), 358–362.
28. [28] Adams, L.A., Lindor, K.D., Angulo, P., The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 99 (2004), 1316–1320.
29. [29] Lindor, K.D., Gershwin, M.E., Poupon, R., Kaplan, M., Bergasa, N.V., Heathcote, E.J., Primary biliary cirrhosis. Hepatology 50 (2009), 291–308.
30. [30] Chapman, R., Fevery, J., Kalloo, A., Nagorney, D.M., Boberg, K.M., Shneider, B., et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 51 (2010), 660–678.
31. [31] Hagan, L., Yang, Z., Ehteshami, M., Schinazi, R., All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. J Viral Hepat 20 (2013), 847–857.
32. [32] Epelboym, I., Winner, M., Allendorf, J.D., MRCP is not a cost-effective strategy in the management of silent common bile duct stones. J Gastrointest Surg 17 (2013), 863–871.
33. [33] Bennett, W.G., Inoue, Y., Beck, J.R., Wong, J.B., Pauker, S.G., Davis, G.L., Estimates of the cost-effectiveness of a single course of interferon-α2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 127 (1997), 855–865.
34. [34] Tapper, E.B., Sengupta, N., Hunink, M.M., Afdhal, N.H., Lai, M., Cost-effective evaluation of nonalcoholic fatty liver disease with NAFLD fibrosis score and vibration controlled transient elastography. Am J Gastroenterol 110 (2015), 1298–1304.
35. [35] Giannini, E.G., Testa, R., Savarino, V., Liver enzyme alteration: a guide for clinicians. Can Med Assoc J 172 (2005), 367–379.
36. [36] Tapper, E.B., Sengupta, N., Lai, M., Horowitz, G., A decision support tool to reduce overtesting for ceruloplasmin and improve adherence with clinical guidelines. JAMA Intern Med, 2015.
37. [37] Rockey, D.C., Caldwell, S.H., Goodman, Z.D., Nelson, R.C., Smith, A.D., Liver biopsy. Hepatology 49 (2009), 1017–1044.
38. [38] Skelly, M.M., James, P.D., Ryder, S.D., Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 35 (2001), 195–199.
39. [39] Aesif, S.W., Parenti, D.M., Lesky, L., Keiser, J.F., A cost-effective interdisciplinary approach to microbiologic send-out test use. Arch Pathol Lab Med 139 (2014), 194–198.
40. [40] Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55 (2012), 2005–2023.
41. [41] Ioannou, G.N., Dominitz, J.A., Weiss, N.S., Heagerty, P.J., Kowdley, K.V., The effect of alcohol consumption on the prevalence of iron overload, iron deficiency, and iron deficiency anemia. Gastroenterology 126 (2004), 1293–1301.
42. [42] Beutler, E., Felitti, V.J., Koziol, J.A., Ho, N.J., Gelbart, T., Penetrance of 845G→ A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 359 (2002), 211–218.
43. [43] Rein, D.B., Smith, B.D., Wittenborn, J.S., Lesesne, S.B., Wagner, L.D., Roblin, D.W., et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in US primary care settings. Ann Intern Med 156 (2012), 263–270.